This study examined three features associated with colorectal carcinoma complicating ulcerative colitis: (a) the distribution of 157 cancers in 120 patients with ulcerative colitis treated at St Mark's Hospital between 1947 and 1992; (b) the frequency at which dysplasia was found at a distance from the tumour in 50 total proctocolectomy specimens in which an average of 27 histology blocks were reviewed, and (c) the five year survival rate according to Dukes's stage and participation in a surveillance programme. Of 157 carcinomas, 88 (56%) occurred in the rectosigmoid, 19 (12%) The presence of dysplasia at a distance from cancer in ulcerative colitis was previously reported to be 96-100%.78 Two studies in the past decade, however, have described an absence of dysplasia in nearly 30% of colectomy specimens containing cancer in colitis.9 10 Because of this, the efficacy of endoscopic surveillance programmes using dysplasia as a marker of neoplasia has been questioned." I Ultimately, the purpose of endoscopic surveillance in ulcerative colitis is to reduce the mortality of cancer associated with this condition. The overall five year survival rate after treatment of cancer in colitis is quoted as 31-55%.3 12-16 None of these reports distinguished patients whose cancer was diagnosed during surveillance.
Despite the large amount of published data regarding colorectal carcinoma complicating ulcerative colitis, details regarding the distribution of cancer and the frequency at which dysplasia occurs at a distance from the malignancy are controversial. These factors, together with the five year survival rate, have implications for the way in which clinicians treat patients with chronic extensive ulcerative colitis.
In contrast with a predominantly distal distribution seen in sporadic colorectal carcinomas, malignancy occurring in ulcerative colitis was originally reported to be distributed uniformly throughout the colon.' 2 More recent reports, however, have described a greater proportion of distal than proximal tumours in this condition.3-6 If this is the case, the use of fibreoptic sigmoidoscopy may have a role in endoscopic surveillance programmes.
The presence of dysplasia at a distance from cancer in ulcerative colitis was previously reported to be 96-100%.78 Two studies in the past decade, however, have described an absence of dysplasia in nearly 30% of colectomy specimens containing cancer in colitis. 9 10 Because of this, the efficacy of endoscopic surveillance programmes using dysplasia as a marker of neoplasia has been questioned." I Ultimately, the purpose of endoscopic surveillance in ulcerative colitis is to reduce the mortality of cancer associated with this condition. The overall five year survival rate after treatment of cancer in colitis is quoted as 31-55%.3 12-16 None of these reports distinguished patients whose cancer was diagnosed during surveillance.
We have examined our own series of patients with colorectal cancer in ulcerative colitis to assess the distribution of malignancy and the frequency at which dysplasia was detected distant to a tumour in recent total proctocolectomy specimens where complete sets of histological slides were available for review. In addition, the overall five year survival of those patients who did or did not participate in a surveillance programme was determined. Twelve malignancies were inoperable, and in these cases the primary tumour was not removed. The operation was palliative in 16 cases in which the tumour was considered to have been incompletely resected by the surgeon. Of the remaining 92 patients who had surgery with the possibility of cure, total proctocolectomy was performed in one or more stages in 66; colectomy and ileorectal anastomosis in five; proctectomy in 14; local excision in one; and segmental colonic resection in six.
Methods
There was clinical evidence of extensive colitis (inflammation proximal to the splenic flexure) in 107 patients, distal colitis in two patients, and in 11 the extent was impossible to assess because the resection was limited. Seventeen patients in whom distal colitis had been diagnosed before surgery developed cancer; at operation, 13 had extensive colitis, two had distal colitis, and in two the extent was not assessed (these patients had limited resections). Seven patients developed malignancy in a distal remnant 8 to 40 years after undergoing colectomy for disabling colitis; the rectum had been defunctioned in one and anastomosed to ileum in six.
Multiple synchronous cancers were found in 25 patients (21%); 18 with two tumours, four with three tumours, one with four tumours, and two with five tumours (total= 157 carcinomas). Table I shows the location of these malignancies. Eighty eight tumours (56%) occurred in the distal colon (rectum or sigmoid colon), 19 (12%) in the descending colon or splenic flexure, and 50 (32%) were in the proximal colon.
Of the 120 patients in this series, carcinoma occurred in the rectum or sigmoid colon in 81 (67.5%). An additional seven patients had carcinoma in the descending colon or splenic flexure, giving a total of 88 patients (73-3%) with malignancy in the left colon. 33-65) . The sites of cancer were rectum (three), sigmoid colon (three), transverse colon (one), and ascending colon (two). All cancers were solitary; four were mucinous and five were non-mucinous. Six tumours were moderately differentiated, one well differentiated, and two poorly differentiated. Dukes's stages were A (two), B (four), and C (two).
Dysplasia was diagnosed either adjacent to or at a distance from a tumour in 41 specimens (82%). This occurred contiguous to a tumour in 39 (78%) and at a distance from a tumour in 37 (74%). Four cases had dysplasia contiguous to a tumour only; 35 had both contiguous and distant dysplasia and two cases exhibited distant dysplasia only. Of the 39 patients with dysplasia adjacent to a tumour, one was classified indefinite, probably positive, 17 were low grade, and 21 were high grade.
Of the 37 cases where dysplasia was diagnosed at a distance from tumour, two were classified indefinite, probably positive, 19 were low grade, and 16 were high grade. In 17 cases there was at least one elevated dysplastic lesion as well as dysplasia in flat mucosa; in one case there was a single elevated dysplastic lesion in the same segment as the tumour without dysplasia elsewhere. Distant dysplasia occurred in the same colonic segment as malignancy in 28 of 37 cases and in segments that did not contain cancer in 26 patients. Distant dysplasia was limited to one colonic segment in 12 specimens and occurred in more than one segment in 25.
Distant dysplasia was confined to the left colon (distal to the transverse colon) in 10 patients, to the right colon (proximal to the splenic flexure) in 10 patients, and occurred in both the right and left colon in 17 patients. Figure 1 shows the distribution of dysplasia in these 37 patients. It will be seen that 20 patients (40%) had dysplasia of the rectum or sigmoid colon. Fifteen of these 20 patients with rectosigmoid dysplasia at a distance from a tumour had carcinoma of the rectum or sigmoid colon; the other five patients had tumours occurring more proximally in the colon (Table II) .
SURVIVAL ANALYSIS
The overall five and 10 year survival rates were 59.4% (95% confidence intervals 49 9 to 67-6%) and 55 3% (95% CI 45*4 to 64-1%). The worst stage of cancer in a given patient was Dukes's A in 32, Dukes's B in 33, Dukes's C in 43, and disseminated in 12. Figure 2 shows the actuarial 10 year survival rates according to the worst stage for all patients. It will be seen that the five and 10 year survival ,~~~~~~~~~~2 4 6 Time from diagnosis of cancer (y) The carcinoma risk in ulcerative colitis considered to be greatest in patients wi chronic extensive disease.23 Only two patients developed colorectal carcinoma less than nine years after the onset of symptoms of ulcerative colitis. In one of these cases, the two events are probably coincidental as bowel symptoms preceded the diagnosis of colitis and carcinoma by only two weeks. Only two of 111 patients in whom the extent of disease was assessed had distal colitis. The remaining 109 patients had clinical evidence of inflammation that extended proximal to the splenic flexure.
Seven patients developed cancer of a distal remnant 8 to 40 years after undergoing colectomy for disabling colitis; in one the 10 rectum was defunctioned and in six it was anastomosed to ileum. Although such operations are sometimes a satisfactory and 'e acceptable method for the treatment of colitis, the risk of cancer in the remaining rectum is well described.24 25 Regular surveillance of % the rectal stump for dysplasia should be to undertaken in any patient treated in this way. %
The presence of dysplasia in the rectal CI biopsy specimens of patients with carcinoma C of the colon was first seen by Morson and id Pang. 7 The true frequency at which dysplasia ad accompanies carcinoma in ulcerative colitis is uncertain. Ransohoff et al reported that 73% as of colorectal carcinomas were associated with ed dysplasia at a distance from the tumour; its in 50% this was high grade dysplasia. In ce that study, 22 resected specimens were ral examined and the mean number of histology as blocks reviewed was 11.9 In a study from ed the Mayo Clinic, mucosal samples were Lot examined from colectomy specimens containing carcinoma associated with ulcerative colitis using endoscopic biopsy forceps in a carefully planned manner so that four specimens were obtained at equal na distances around the circumference of the ly colon at intervals of 10 cm along its length. id Dysplasia was detected distant to malignancy ed in 74% of specimens: this was classified as high th grade in 32%, low grade in 34%, and probably / positive in 80/o.10 th Our review of 50 proctocolectomy specimens nt entailed an examination of an average of 27 hisng tology blocks from various colonic sites. or Dysplasia was absent in nine patients (18%), he present adjacent to a tumour in 39 (78%), and ts, distant from a malignancy in 37 (74%). There he was no difference in the number of histology blocks examined in the specimens with and iat without dysplasia. Sixteen cases (32%) of he distant dysplasia were high grade, 19 were ad low grade (38%), and two were indefinite, probid ably positive (4%). These results are virtually he identical to those reported by Taylor et al. 0 at Dysplasia at a distance from malignancy was ds detected equally in the right and left colon. Of ur 37 patients with distant dysplasia, dysplasia al was confined to the left colon in 10, the right te colon in 10, and in both the right and left colon Lal in 17. Dysplasia at a distance from a tumour is was detected in the rectum or sigmoid colon in lic 20 cases (40%); however, 15 of these cases had tumours occurring in the rectosigmoid and is only five had tumours that were found more th proximally (Table II) .
It is still unclear if failure to detect dysplasia at a distance from malignancy in approximately 25-30% of patients with cancer associated with ulcerative colitis is a result of inadequate sampling or a true absence of this feature. Despite the rigorous sampling undertaken in this series and in the study reported by Taylor et al,1I the incidence of dysplasia was similar to the results obtained by Ransohoff et al.9 Except for an absence of multifocal tumours, there was no important difference in the clinical or pathological records in this series of patients to distinguish those in whom dysplasia was absent at a distance from cancer, from those in whom distant dysplasia was present. Results from an endoscopic surveillance programme suggest that patients without dysplasia at operation are those in whom dysplasia is not detected preoperatively. 26 The weight of all this evidence suggests that, although a localised dysplastic lesion may precede development of a carcinoma, and may thus be potentially identifiable at a pre-cancerous stage, in about a quarter of cases no dysplasia is detectable at a distance from this site.
Although the prognosis of carcinoma occurring in ulcerative colitis had been previously regarded as grave,27 recent reports suggest that it is similar to sporadic colorectal carcinoma.12-16 Cumulative five year survival rates according to Duke's stage in the 120 patients were 906% for Dukes's A tumours, 87-8% for Dukes's B tumours, and 28-3% for Dukes's C tumours. No patient with disseminated malignancy survived longer than one year. The 10 year survival rates were 82-2%, 87 8%, and 22 7% for Dukes A, B, and C tumours respectively. These results, which are similar to other reports13 16 support the proposition that early diagnosis of cancer should improve survival.
While it has not been established that surveillance for cancer in ulcerative colitis is associated with an improved survival, we have assessed the respective outcomes of patients whose malignancy occurred during surveillance and those whose cancer developed outside a surveillance programme. The overall five year survival rate for the 16 patients whose cancer was diagnosed during surveillance was 87% compared with 55% of those who did not participate in surveillance (p=0024). The number of cases developing cancer during surveillance was small and although this result is statistically significant, confirmatory evidence from other series is needed before it is concluded that surveillance improves survival in colorectal carcinoma complicating ulcerative colitis.
CLINICAL SIGNIFICANCE OF FINDINGS
Firstly, two thirds of patients with carcinoma complicating ulcerative colitis had tumours arising in the rectum or sigmoid colon. Among 40%/ of patients who had dysplasia in the rectosigmoid, one quarter had a tumour situated more proximally in the colon. Thus, almost 75%/ of patients with carcinoma in colitis had pre-cancer or cancer in the rectum or sigmoid colon. These findings support the use of flexible sigmoidoscopy in surveillance programmes as an additional investigation to colonoscopy, which would still be required to detect malignancy and dysplasia arising in the proximal colon. Secondly, the frequency at which dysplasia occurs at a distance from a tumour was 74%/o. This result suggests that endoscopic surveillance using dysplasia as a marker of neoplasia will be unsuccessful in preventing carcinoma in almost one quarter of patients. New predictors of cancer are urgently required for this group of patients in whom no satisfactory marker of premalignancy is currently available. Thirdly, the five year survival varied according to the Dukes's stage of cancer, suggesting that as in sporadic colorectal carcinoma, early diagnosis will probably improve survival.
